Document:

Exhibit 10.8
                                OPTION AGREEMENT

         Option agreement dated as of June 1, 2001 between B. TWELVE, INC., a
corporation existing under the laws of the State of Florida (the "Corporation")
and URI SAGMAN, an individual residing in the Province of Ontario (the
"Optionee").

         WHEREAS the Optionee is an employee of the Corporation and plans to
render faithful and efficient service to the Corporation in that capacity,

         AND WHEREAS the Corporation desires to continue to receive the benefit
of the services of the Optionee and to more fully identify his interest with the
Corporation's future and success,

         AND WHEREAS the corporate milestones for the Corporation are correlated
with the anticipated progress in the scientific research and corporate
development of the Corporation.

Specifically, the Scientific and Corporate objectives of the Corporation are
aligned with the planned research and development of the following two (2)
scientific platforms (each a "Scientific Platform" and collectively, the
"Scientific Platforms") and one (1) corporate target (the "Corporate Target"):

1.       Vitamin B12 analogues - these are chemically modified Vitamin B12
         molecules that are targeted to the Vitamin B12 receptor with potential
         applications for the treatment of patients with either cancer or some
         forms of arthritis or potentially other diseases of the immune system.

2.       Antibodies to Transcobalamin II - Transcobalamin II ("TC II") is a
         protein that is found in the blood stream. Vitamin B12 combines with TC
         II in the blood stream and in turn the Vitamin B12 and TC II complex
         combines with the Vitamin B12 receptor on the cell surface. Monoclonal
         antibodies to TC II are aimed at inhibiting the binding of TC II alone
         or combined with Vitamin B12 to bind to the Vitamin B12 receptor.

3.       Corporate Target - The Company is seeking financing opportunities and
         is pursuing strategic alliance negotiations intended to provide near
         term revenues through licensing, milestone and royalty payments,
         thereby offsetting the risk associated with more medium term
         opportunities.

The milestones outlined below (each a "Milestone" and collectively, the
"Milestones") describe the anticipated achievements of the scientific and
corporate effort of the Corporation with regard to the Scientific Platforms and
Corporate Strategy above described.

                                   Page 1 of 8
<PAGE>

         With respect to the "Vitamin B12 analogues" Scientific Platform, there
are two (2) Milestones described as follows:

First Milestone

Demonstration that new Vitamin B12 analogues are active in cell culture
bioassays. New Vitamin B12 analogues have been developed by the Corporation.
Existing or new Vitamin B12 analogues are to be characterized by their ability
to alter the biological activity (i.e. apoptosis) of either cancer cells, cells
of the immune system or other appropriate cell culture bioassays.

Second Milestone

Demonstration that new Vitamin B12 analogues are active in animal models.
Selected candidates (Vitamin B12 analogues) obtained in sufficient quantities
are to be tested in animal models for biological activity against cancer, for
modulation of the immune system or other appropriate standard systems.

With respect to the "Antibodies to Transcobalamin II" Scientific Platform, there
is one (1) Milestone described as follows:

Third Milestone

Pre-clinical advancement of human monoclonal antibody candidate(s) to the TC II
protein or to the TCII-Vitamin B12 complex or to the vitamin B12 pathway.
Specific type(s) of monoclonal antibodies are currently being selected and
characterized to a form suitable for administration to human administration in
anticipation of filing an IND or equivalent. Selected monoclonal antibody(ies)
candidate(s) is to be selected. This step is anticipated to be a requirement to
initiate with manufacturing and acute toxicity studies in anticipation of the
filing of an IND or equivalent.

With respect to the "Corporate Target", there is three (3) Milestones described
as follows:

Fourth Milestone

The Company is seeking financing opportunities. The Company needs to secure a
minimum financing of $2,000,000 through one or a series of financing. Under this
milestone, the financing is to be effected for cash, unless otherwise agreed by
the Board of Directors.

Fifth Milestone

The Company is seeking substantial financing opportunities. In addition to the
previous $2,000,000 raised, the Company is to secure an additional financing of
$3,000,000 for a total of $5,000,000 through one or a series of financing. Under
this milestone, the financing is to be effected for cash, unless otherwise
agreed by the Board of Directors.

                                   Page 2 of 8
<PAGE>

Sixth Milestone

The Company is pursuing strategic alliance negotiations. Those strategic
alliance negotiations are intended to but not limited to provide near and long
term revenues through licensing, milestone and royalty payments, thereby
offsetting the risk associated with more medium term opportunities. Also, should
be considered the intangible aspect of the agreement(s) in terms of increasing
the corporate profile and validating the technology.

The above milestones are hereinafter referred to as the "First Milestone",
"Second Milestone", Third Milestone", "Fourth Milestone", "Fifth Milestone", and
"Sixth Milestone", respectively.

         NOW THEREFORE in consideration of the foregoing, the sum of $10.00 and
the mutual agreements contained herein and other good and valuable consideration
(the receipt and sufficiency of which are hereby acknowledged), the parties
hereto agree as follows:

1.       Option to Purchase. The Corporation hereby grants to the Optionee, on
         and subject to the terms and conditions hereinafter set forth, the
         irrevocable right and option (the "Option") exercisable in accordance
         with the terms of this Agreement to purchase from the Corporation a
         maximum of 612,500 authorized and unissued common shares in the capital
         of the Corporation (the "Optioned Shares") at purchase price of $.0001
         per Optioned Share (the "Option Price").

2.       Vesting of the Option.

         (a)      The Option shall vest with respect to 130,000 of the Optioned
                  Shares (the "First Milestone Optioned Shares"), upon the
                  achievement by the Optionee of all parts of the First
                  Milestone, which the Optionee is to use his best efforts to
                  achieve on or before March 31, 2002.

         (b)      The Option shall vest with respect to 220,000 of the Optioned
                  Shares (the "Second Milestone Optioned Shares"), upon the
                  achievement by the Optionee of the Second Milestone, which the
                  Optionee is to use his best efforts to achieve on or before
                  March 31, 2002.

         (c)      The Option shall vest with respect to 80,000 of the Optioned
                  Shares (the "Third Milestone Optioned Shares"), upon the
                  achievement by the Optionee of all parts of the Third
                  Milestone, which the Optionee is to use his best efforts to
                  achieve on or before December 31, 2002.

         (d)      The Option shall vest with respect to 68,000 of the Optioned
                  Shares (the "Fourth Milestone Optioned Shares"), upon the
                  achievement by the Optionee of the Fourth Milestone, which the
                  Optionee is to use his best efforts to achieve on or before
                  December 15, 2001.

                                   Page 3 of 8
<PAGE>

         (e)      The Option shall vest with respect to 68,000 of the Optioned
                  Shares (the "Fifth Milestone Optioned Shares"), upon the
                  achievement by the Optionee of the Fifth Milestone, which the
                  Optionee is to use his best efforts to achieve on or before
                  August 31, 2002.

         (f)      The Option shall vest with respect to 46,500 of the Optioned
                  Shares (the "Sixth Milestone Optioned Shares"), upon the
                  achievement by the Optionee of the Sixth Milestone, which the
                  Optionee is to use his best efforts to achieve on or before
                  June 30, 2003.

         (g)      Notwithstanding the vesting requirements set out in
                  subsections 2(a) through (f) above, all Optioned Shares not
                  already vested shall vest immediately in the event of the
                  following:

                  (i)      the sale of all or substantially all of the
                           Corporation's assets for net proceeds to the
                           Corporation of $25,000,000, of which $10,000,000 has
                           to be in cash;

                  (ii)     the sale of all the shares of the Corporation,
                           excluding a reverse take-over transaction; and

                  (iii)    the termination without Cause (as defined below) of
                           Sagman as an employee of the Corporation.

         In this agreement, "Cause" shall mean:

                  (i)      fraud, embezzlement or gross insubordination on the
                           part of the Optionee;

                  (ii)     conviction or the entry of a plea of nolo contendere
                           by the Optionee for any felony or indictable offence;

                  (iii)    a material breach of, or the willful failure or
                           refusal by the Optionee to perform and discharge, his
                           duties, responsibilities or obligations under any
                           agreement with the Corporation or any of its
                           subsidiaries or affiliates that is related to the
                           Optionee's employment with the Corporation (other
                           than by reason of disability or death) that is not
                           corrected with thirty (30) days immediately following
                           written notice to the Optionee by the Corporation,
                           such notice to state with specificity the nature of
                           the breach, failure or refusal; provided that it such
                           breach, failure or refusal cannot reasonably be
                           corrected within thirty (30) days of written notice
                           thereof, correction shall be commenced by the
                           Optionee within such thirty (30) day period and
                           completed within a reasonable period thereafter; or

                  (iv)     any act of willful misconduct by the Optionee with
                           (A) is intended to result in substantial personal
                           enrichment of the Optionee at the expense of the
                           Corporation or any of its subsidiaries or affiliates,
                           or (B) has a material adverse impact on the business
                           or reputation of the Corporation or any of its
                           subsidiaries or affiliates (such determination to be
                           made by the Board in its reasonable judgment).

                                   Page 4 of 8
<PAGE>

         (h)      Notwithstanding the dates prescribed for vesting set out in
                  subsection 2(a) through (f) above, all Optioned Shares not
                  already vested shall vest immediately upon filing of an IND or
                  equivalent.

(3)      Exercise of Option. The Option with respect to vested Optioned Shares
         shall be exercisable prior to the end of the Term.

(4)      Term.

         (a)      Subject to Subsection 4(b) below, the Option shall be
                  exercisable until five (5) years from the date the Option is
                  granted (the "Term"). At the end of the Term, all vested or
                  unvested Options granted hereunder shall expire and shall no
                  longer be exercisable.

         (b)

                  (i)      If the Optionee ceases to be an employee of the
                           Corporation by reason of his death or voluntary
                           resignation:

                           (A)      Any vested Options shall be exercisable by
                                    the Optionee or his estate, as the case may
                                    be, until the first (1st) anniversary of the
                                    date of the Optionee's death or voluntary
                                    resignation.

                           (B)      The vesting of Options held by the Optionee
                                    automatically shall cease on the date of the
                                    Optionee's death or voluntary resignation.

                  (ii)     If the Optionee is terminated for Cause, any vested
                           Options held by the Optionee shall be exercisable by
                           the Optionee for a period of three (3) months from
                           termination; provided however, if the Optionee is
                           dismissed for Cause and the Corporation achieves one
                           or more Milestones in the three (3) month period
                           subsequent to his dismissal, the Optionee shall be
                           entitled to exercise the Optioned Shares relating to
                           such Milestone(s) for a further period of thirty (30)
                           days from the date in which the Optionee is informed
                           that such Milestone(s) was achieved.

                  (iii)    If the Optionee is terminated otherwise than for
                           Cause, any vested Options held by the Optionee shall
                           be exercisable by the Optionee for a period of three
                           (3) months from termination.

                                   Page 5 of 8
<PAGE>

Manner of Exercise of Option. During the Term, the Optionee, subject to the
provisions of this Agreement, may exercise the Option to purchase on a
cumulative basis, to the extent hereinafter provided, all or any part of the
number of Shares subject to the Option which have vested in accordance with
Section 2 until the total number of Optioned Shares subject to the Option stated
in Section 1 has been purchased; provided, however, that the Option may only be
exercised (in each case to the nearest full Optioned Share) during the Term and
in units of 25,000 Optioned Shares or such fewer number of Optioned Shares as
may remain subject to this Option.

6.       Notice of Exercise of Option. This Option shall be exercised upon
         providing notice in writing to the Corporation addressed to Corporation
         at such place as the Corporation's executive office may then be located
         (the "Notice"), which Notice shall indicate the number of Optioned
         Shares (which have vested) for which the Option is being exercised, and
         which Notice shall be accompanied by payment in full to the Corporation
         of the Option Price for such Optioned Shares in cash or by certified
         cheque.

7.       Right of a Shareholder. After receipt of (i) a Notice, and (ii) payment
         in full of the Option Price for the Optioned Shares for which the
         Option is being exercised, the Corporation shall, within five (5)
         business days, take all actions necessary to issue such Optioned Shares
         to the Optionee and to prepare and deliver share certificates
         representing such Optioned Shares so issued and register such Optioned
         Shares in the name of the Optionee. The Optionee shall have no right as
         a shareholder with respect to such Optioned Shares until the issuance
         of such share certificates, and no adjustment shall be made for
         dividends or other rights for which the record date is prior to the
         time such share certificates are issued. The Corporation shall deliver
         share certificates in respect of such Optioned Shares within five (5)
         business days after receipt of items (i) and (ii) above. The issuance
         of the Optioned Shares is conditional upon the Optionee entering into
         an agreement with the other shareholders of the Corporation agreeing to
         be bound by the provisions of the Amended and Restated Unanimous
         Shareholders Agreement dated January 15, 2001 among the Corporation and
         its shareholders in respect of the Optioned Shares.

8.       Transfer of Option. The Option granted pursuant to this Agreement shall
         not be assignable or transferable by the Optionee, except to members of
         the Optionee's immediate family provided that the Optionee continues to
         be bound by the provisions of this Agreement.

9.       Adjustment. In the event that prior to the exercise of the Option,
         there is any change in the number of outstanding common shares of the
         Corporation as a result of (i) the consolidation, merger or
         amalgamation of the Corporation with or into another body corporate;
         (ii) the conversion, exchange, redesignation, reclassification,
         consolidation or subdivision of the common shares; or (iii) any other
         capital reorganization of the Corporation whether by reorganization,
         arrangement, stock dividend, transfer, sale, continuance or otherwise,
         then the number of the Optioned Shares subject to the Option and the
         Option Price thereof shall be adjusted appropriately.

                                   Page 6 of 8
<PAGE>

10.      Necessary Approvals. The obligation of the Corporation to sell and
         deliver the Optioned Shares on the exercise of the Option is subject to
         the approval of any governmental authority or stock exchanges on which
         the shares in the capital of the Corporation are listed for trading
         which may be required in connection with the authorization, issuance or
         sale of the Optioned Shares by the Corporation. If any of the Optioned
         Shares cannot be issued to any Optionee after the exercise of the
         Option therefor for any reason including, without limitation, the
         failure to obtain such approval, then the obligation of the Corporation
         to issue such Optioned Shares shall terminate and any Option Price paid
         to the Corporation shall be returned to the Optionee.

11.      Changes to Milestones or Scientific Platforms. The parties to this
         Agreement recognize, that it is conceivable that the Milestones
         described in this Agreement may have to be altered or adjusted, from
         time to time, based on the actual results of the scientific research or
         corporate activities conducted by the Corporation or as new approaches
         to scientific research evolve. The parties to this Agreement agree that
         any new approaches and changes in direction of the Corporation's
         Scientific Platforms and Corporate Target, must be approved by the
         Board of Directors.

         In the event one or more new Milestones or one of the existing
         Scientific Platforms or Corporate Target should be altered or
         discontinued by the Corporation, the parties further acknowledge that
         the Board of Directors of the Corporation shall have the power and
         discretion to vest, substitute or cancel any or all of the options
         allocated to existing Milestones.

12.      Currency. All monetary amounts in this Agreement refer to lawful money
         of the United States of America, unless specified.

13       Governing Law. This Agreement and the Option shall be governed by and
         interpreted and enforced in accordance with the laws of the State of
         Florida and the federal laws of the United States of America applicable
         therein.

14.      Enurement. This Agreement shall enure to the befit of and be binding
         upon the parties hereto and their respective heirs, executors,
         successors and permitted assigns.

                                   Page 7 of 8
<PAGE>

         IN WITNESS WHEREOF the parties have caused this option agreement to be
executed by their respective duly authorized officers.

                                           B. TWELVE, INC.

                                           Per:
                                           -------------------------------

----------------------------------         -------------------------------
Witness:                                   Uri Sagman

                           By Signing, Dr. Sagman acknowledges that he
                           understands the contents of this Agreement and that
                           he has been given the opportunity to obtain
                           independent legal advice and has either done so or
                           has chosen not to obtain such advice.

                                   Page 8 of 8Exhibit 10.9
                                OPTION AGREEMENT

         Option agreement dated as of June 1, 2001 between B. TWELVE, INC., a
corporation existing under the laws of the State of Florida (the "Corporation")
and JEAN-LUC BERGER, an individual residing in the Province of Ontario (the
"Optionee").

         WHEREAS the Optionee is an employee of the Corporation and plans to
render faithful and efficient service to the Corporation in that capacity,

         AND WHEREAS the Corporation desires to continue to receive the benefit
of the services of the Optionee and to more fully identify his interest with the
Corporation's future and success,

         AND WHEREAS the corporate milestones for the Corporation are correlated
with the anticipated progress in the scientific research and corporate
development of the Corporation.

Specifically, the Scientific and Corporate objectives of the Corporation are
aligned with the planned research and development of the following two (2)
scientific platforms (each a "Scientific Platform" and collectively, the
"Scientific Platforms") and one (1) corporate target (the "Corporate Target"):

1.       VITAMIN B12 ANALOGUES - these are chemically modified Vitamin B12
         molecules that are targeted to the Vitamin B12 receptor with potential
         applications for the treatment of patients with either cancer or some
         forms of arthritis or potentially other diseases of the immune system.

2.       ANTIBODIES TO TRANSCOBALAMIN II - Transcobalamin II ("TC II") is a
         protein that is found in the blood stream. Vitamin B12 combines with TC
         II in the blood stream and in turn the Vitamin B12 and TC II complex
         combines with the Vitamin B12 receptor on the cell surface. Monoclonal
         antibodies to TC II are aimed at inhibiting the binding of TC II alone
         or combined with Vitamin B12 to bind to the Vitamin B12 receptor.

3.       CORPORATE TARGET - The Company is seeking financing opportunities and
         is pursuing strategic alliance negotiations intended to provide near
         term revenues through licensing, milestone and royalty payments,
         thereby offsetting the risk associated with more medium term
         opportunities.

The milestones outlined below (each a "Milestone" and collectively, the
"Milestones") describe the anticipated achievements of the scientific and
corporate effort of the Corporation with regard to the Scientific Platforms and
Corporate Strategy above described.

                                  Page 1 of 8
<PAGE>

         With respect to the "Vitamin B12 analogues" Scientific Platform, there
are two (2) Milestones described as follows:

FIRST MILESTONE

Demonstration that new Vitamin B12 analogues are active in cell culture
bioassays. New Vitamin B12 analogues have been developed by the Corporation.
Existing or new Vitamin B12 analogues are to be characterized by their ability
to alter the biological activity (i.e. apoptosis) of either cancer cells, cells
of the immune system or other appropriate cell culture bioassays.

SECOND MILESTONE

Demonstration that new Vitamin B12 analogues are active in animal models.
Selected candidates (Vitamin B12 analogues) obtained in sufficient quantities
are to be tested in animal models for biological activity against cancer, for
modulation of the immune system or other appropriate standard systems.

With respect to the "Antibodies to Transcobalamin II" Scientific Platform, there
is one (1) Milestone described as follows:

THIRD MILESTONE

Pre-clinical advancement of human monoclonal antibody candidate(s) to the TC II
protein or to the TCII-Vitamin B12 complex or to the vitamin B12 pathway.
Specific type(s) of monoclonal antibodies are currently being selected and
characterized to a form suitable for administration to human administration in
anticipation of filing an IND or equivalent. Selected monoclonal antibody(ies)
candidate(s) is to be selected. This step is anticipated to be a requirement to
initiate with manufacturing and acute toxicity studies in anticipation of the
filing of an IND or equivalent.

With respect to the "Corporate Target", there is three (3) Milestones described
as follows:

FOURTH MILESTONE

The Company is seeking financing opportunities. The Company needs to secure a
minimum financing of $2,000,000 through one or a series of financing. Under this
milestone, the financing is to be effected for cash, unless otherwise agreed by
the Board of Directors.

FIFTH MILESTONE

The Company is seeking substantial financing opportunities. In addition to the
previous $2,000,000 raised, the Company is to secure an additional financing of
$3,000,000 for a total of $5,000,000 through one or a series of financing. Under
this milestone, the financing is to be effected for cash, unless otherwise
agreed by the Board of Directors.

                                  Page 2 of 8
<PAGE>

SIXTH MILESTONE

The Company is pursuing strategic alliance negotiations. Those strategic
alliance negotiations are intended to but not limited to provide near and long
term revenues through licensing, milestone and royalty payments, thereby
offsetting the risk associated with more medium term opportunities. Also, should
be considered the intangible aspect of the agreement(s) in terms of increasing
the corporate profile and validating the technology.

The above milestones are hereinafter referred to as the "First Milestone",
"Second Milestone", Third Milestone", "Fourth Milestone", "Fifth Milestone", and
"Sixth Milestone", respectively.

         NOW THEREFORE in consideration of the foregoing, the sum of $10.00 and
the mutual agreements contained herein and other good and valuable consideration
(the receipt and sufficiency of which are hereby acknowledged), the parties
hereto agree as follows:

1.       OPTION TO PURCHASE. The Corporation hereby grants to the Optionee, on
         and subject to the terms and conditions hereinafter set forth, the
         irrevocable right and option (the "Option") exercisable in accordance
         with the terms of this Agreement to purchase from the Corporation a
         maximum of 137,500 authorized and unissued common shares in the capital
         of the Corporation (the "Optioned Shares") at purchase price of $.0001
         per Optioned Share (the "Option Price").

2.       VESTING OF THE OPTION.

         (a)      The Option shall vest with respect to 30,000 of the Optioned
                  Shares (the "First Milestone Optioned Shares"), upon the
                  achievement by the Optionee of all parts of the First
                  Milestone, which the Optionee is to use his best efforts to
                  achieve on or before March 31, 2002.

         (b)      The Option shall vest with respect to 50,000 of the Optioned
                  Shares (the "Second Milestone Optioned Shares"), upon the
                  achievement by the Optionee of the Second Milestone, which the
                  Optionee is to use his best efforts to achieve on or before
                  March 31, 2002.

         (c)      The Option shall vest with respect to 17,500 of the Optioned
                  Shares (the "Third Milestone Optioned Shares"), upon the
                  achievement by the Optionee of all parts of the Third
                  Milestone, which the Optionee is to use his best efforts to
                  achieve on or before December 31, 2002.

         (d)      The Option shall vest with respect to 15,000 of the Optioned
                  Shares (the "Fourth Milestone Optioned Shares"), upon the
                  achievement by the Optionee of the Fourth Milestone, which the
                  Optionee is to use his best efforts to achieve on or before
                  December 15, 2001.

                                  Page 3 of 8
<PAGE>

         (e)      The Option shall vest with respect to 15,000 of the Optioned
                  Shares (the "Fifth Milestone Optioned Shares"), upon the
                  achievement by the Optionee of the Fifth Milestone, which the
                  Optionee is to use his best efforts to achieve on or before
                  August 31, 2002.

         (f)      The Option shall vest with respect to 10,000 of the Optioned
                  Shares (the "Sixth Milestone Optioned Shares"), upon the
                  achievement by the Optionee of the Sixth Milestone, which the
                  Optionee is to use his best efforts to achieve on or before
                  June 30, 2003.

         (g)      Notwithstanding the vesting requirements set out in
                  subsections 2(a) through (f) above, all Optioned Shares not
                  already vested shall vest immediately in the event of the
                  following:

                  (i)      the sale of all or substantially all of the
                           Corporation's assets for net proceeds to the
                           Corporation of $25,000,000, of which $10,000,000 has
                           to be in cash;
                  (ii)     the sale of all the shares of the Corporation,
                           excluding a reverse take-over transaction; and
                  (iii)    the termination without Cause (as defined below) of
                           Berger as an employee of the Corporation.

         In this agreement, "Cause" shall mean:

                  (i)      fraud, embezzlement or gross insubordination on the
                           part of the Optionee;
                  (ii)     conviction or the entry of a plea of nolo contendere
                           by the Optionee for any felony or indictable offence;
                  (iii)    a material breach of, or the willful failure or
                           refusal by the Optionee to perform and discharge, his
                           duties, responsibilities or obligations under any
                           agreement with the Corporation or any of its
                           subsidiaries or affiliates that is related to the
                           Optionee's employment with the Corporation (other
                           than by reason of disability or death) that is not
                           corrected with thirty (30) days immediately following
                           written notice to the Optionee by the Corporation,
                           such notice to state with specificity the nature of
                           the breach, failure or refusal; provided that it such
                           breach, failure or refusal cannot reasonably be
                           corrected within thirty (30) days of written notice
                           thereof, correction shall be commenced by the
                           Optionee within such thirty (30) day period and
                           completed within a reasonable period thereafter; or
                  (iv)     any act of willful misconduct by the Optionee with
                           (A) is intended to result in substantial personal
                           enrichment of the Optionee at the expense of the
                           Corporation or any of its subsidiaries or affiliates,
                           or (B) has a material adverse impact on the business
                           or reputation of the Corporation or any of its
                           subsidiaries or affiliates (such determination to be
                           made by the Board in its reasonable judgment).

                                  Page 4 of 8
<PAGE>

         (h)      Notwithstanding the dates prescribed for vesting set out in
                  subsection 2(a) through (f) above, all Optioned Shares not
                  already vested shall vest immediately upon filing of an IND or
                  equivalent.

(3)      EXERCISE OF OPTION. The Option with respect to vested Optioned Shares
         shall be exercisable prior to the end of the Term.

(4)      TERM.

         (a)      Subject to Subsection 4(b) below, the Option shall be
                  exercisable until five (5) years from the date the Option is
                  granted (the "Term"). At the end of the Term, all vested or
                  unvested Options granted hereunder shall expire and shall no
                  longer be exercisable.

         (b)

                  (i)      If the Optionee ceases to be an employee of the
                           Corporation by reason of his death or voluntary
                           resignation:

                           (A)      Any vested Options shall be exercisable by
                                    the Optionee or his estate, as the case may
                                    be, until the first (1st) anniversary of the
                                    date of the Optionee's death or voluntary
                                    resignation.

                           (B)      The vesting of Options held by the Optionee
                                    automatically shall cease on the date of the
                                    Optionee's death or voluntary resignation.

                  (ii)     If the Optionee is terminated for Cause, any vested
                           Options held by the Optionee shall be exercisable by
                           the Optionee for a period of three (3) months from
                           termination; provided however, if the Optionee is
                           dismissed for Cause and the Corporation achieves one
                           or more Milestones in the three (3) month period
                           subsequent to his dismissal, the Optionee shall be
                           entitled to exercise the Optioned Shares relating to
                           such Milestone(s) for a further period of thirty (30)
                           days from the date in which the Optionee is informed
                           that such Milestone(s) was achieved.

                  (iii)    If the Optionee is terminated otherwise than for
                           Cause, any vested Options held by the Optionee shall
                           be exercisable by the Optionee for a period of three
                           (3) months from termination.

                                  Page 5 of 8
<PAGE>

5.       MANNER OF EXERCISE OF OPTION. During the Term, the Optionee, subject to
         the provisions of this Agreement, may exercise the Option to purchase
         on a cumulative basis, to the extent hereinafter provided, all or any
         part of the number of Shares subject to the Option which have vested in
         accordance with Section 2 until the total number of Optioned Shares
         subject to the Option stated in Section 1 has been purchased; provided,
         however, that the Option may only be exercised (in each case to the
         nearest full Optioned Share) during the Term and in units of 10,000
         Optioned Shares or such fewer number of Optioned Shares as may remain
         subject to this Option.

6.       NOTICE OF EXERCISE OF OPTION. This Option shall be exercised upon
         providing notice in writing to the Corporation addressed to Corporation
         at such place as the Corporation's executive office may then be located
         (the "Notice"), which Notice shall indicate the number of Optioned
         Shares (which have vested) for which the Option is being exercised, and
         which Notice shall be accompanied by payment in full to the Corporation
         of the Option Price for such Optioned Shares in cash or by certified
         cheque.

7.       RIGHT OF A SHAREHOLDER. After receipt of (i) a Notice, and (ii) payment
         in full of the Option Price for the Optioned Shares for which the
         Option is being exercised, the Corporation shall, within five (5)
         business days, take all actions necessary to issue such Optioned Shares
         to the Optionee and to prepare and deliver share certificates
         representing such Optioned Shares so issued and register such Optioned
         Shares in the name of the Optionee. The Optionee shall have no right as
         a shareholder with respect to such Optioned Shares until the issuance
         of such share certificates, and no adjustment shall be made for
         dividends or other rights for which the record date is prior to the
         time such share certificates are issued. The Corporation shall deliver
         share certificates in respect of such Optioned Shares within five (5)
         business days after receipt of items (i) and (ii) above. The issuance
         of the Optioned Shares is conditional upon the Optionee entering into
         an agreement with the other shareholders of the Corporation agreeing to
         be bound by the provisions of the Amended and Restated Unanimous
         Shareholders Agreement dated January 15, 2001 among the Corporation and
         its shareholders in respect of the Optioned Shares.

8.       TRANSFER OF OPTION. The Option granted pursuant to this Agreement shall
         not be assignable or transferable by the Optionee, except to members of
         the Optionee's immediate family provided that the Optionee continues to
         be bound by the provisions of this Agreement.

9.       ADJUSTMENT. In the event that prior to the exercise of the Option,
         there is any change in the number of outstanding common shares of the
         Corporation as a result of (i) the consolidation, merger or
         amalgamation of the Corporation with or into another body corporate;
         (ii) the conversion, exchange, redesignation, reclassification,
         consolidation or subdivision of the common shares; or (iii) any other
         capital reorganization of the Corporation whether by reorganization,
         arrangement, stock dividend, transfer, sale, continuance or otherwise,
         then the number of the Optioned Shares subject to the Option and the
         Option Price thereof shall be adjusted appropriately.

                                  Page 6 of 8
<PAGE>

10.      NECESSARY APPROVALS. The obligation of the Corporation to sell and
         deliver the Optioned Shares on the exercise of the Option is subject to
         the approval of any governmental authority or stock exchanges on which
         the shares in the capital of the Corporation are listed for trading
         which may be required in connection with the authorization, issuance or
         sale of the Optioned Shares by the Corporation. If any of the Optioned
         Shares cannot be issued to any Optionee after the exercise of the
         Option therefor for any reason including, without limitation, the
         failure to obtain such approval, then the obligation of the Corporation
         to issue such Optioned Shares shall terminate and any Option Price paid
         to the Corporation shall be returned to the Optionee.

11.      CHANGES TO MILESTONES OR SCIENTIFIC PLATFORMS. The parties to this
         Agreement recognize, that it is conceivable that the Milestones
         described in this Agreement may have to be altered or adjusted, from
         time to time, based on the actual results of the scientific research or
         corporate activities conducted by the Corporation or as new approaches
         to scientific research evolve. The parties to this Agreement agree that
         any new approaches and changes in direction of the Corporation's
         Scientific Platforms and Corporate Target, must be approved by the
         Board of Directors.

         In the event one or more new Milestones or one of the existing
         Scientific Platforms or Corporate Target should be altered or
         discontinued by the Corporation, the parties further acknowledge that
         the Board of Directors of the Corporation shall have the power and
         discretion to vest, substitute or cancel any or all of the options
         allocated to existing Milestones.

12.      CURRENCY. All monetary amounts in this Agreement refer to lawful money
         of the United States of America, unless specified.

13       GOVERNING LAW. This Agreement and the Option shall be governed by and
         interpreted and enforced in accordance with the laws of the State of
         Florida and the federal laws of the United States of America applicable
         therein.

14.      ENUREMENT. This Agreement shall enure to the befit of and be binding
         upon the parties hereto and their respective heirs, executors,
         successors and permitted assigns.

                                  Page 7 of 8
<PAGE>

         IN WITNESS WHEREOF the parties have caused this option agreement to be
executed by their respective duly authorized officers.

         B. TWELVE, INC.

                                              Per:
                                                      -------------------------

--------------------------                            -------------------------
Witness:                                              Jean-Luc Berger

By Signing, Dr. Berger acknowledges that he understands
the contents of this Agreement and that he has been given
the opportunity to obtain independent legal advice and has
either done so or has chosen not to obtain such advice.

                                  Page 8 of 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}]]